Pfizer Ltd Q1 net profit rises 6.7% to ₹205 crore as EBITDA margin expands to 38%
AI Market Summary
Pfizer Ltd.'s June-quarter results showed modest topline and profit growth, with EBITDA up 18% and margin expanding to 38%, indicating improved operating leverage. The stock reaction was muted (+0.47%), suggesting the print was largely in line with expectations. As a single-company earnings update in an India-listed subsidiary, the broader cross-asset and crypto impact is limited, though it supports a stable tone for pharma defensives.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT-1.67%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Pfizer Ltd.’s Indian unit, Pfizer Ltd., reported Q1 FY2024 net profit up 6.7% year on year to ₹205 crore, while revenue from operations rose 8.3% to ₹653 crore. EBITDA increased 18% to ₹248 crore and the EBITDA margin widened to 38% from 35%. After the results, the stock was up 0.47% at ₹4,712.05.
